Core Viewpoint - The announcement details the lifting of the lock-up period for certain shareholders of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd., allowing for the circulation of previously restricted shares after fulfilling specific commitments [1][2]. Group 1: Share Issuance and Lock-up Period - The company issued 27,041,667 shares during its initial public offering (IPO) on December 20, 2021, resulting in a total share capital of 81,125,000 shares before the IPO and 108,166,667 shares after [1]. - The lock-up period for the shares was initially set at 36 months from the IPO date, which has been extended by an additional 6 months due to the stock price falling below the IPO price for 20 consecutive trading days [15]. Group 2: Shareholder Commitments - Shareholders applying for the lifting of the lock-up include Shao Chunneng, Lou Jinfang, You Minwei, and several investment management partnerships, all of whom have committed to not transferring their shares for 36 months post-IPO [2][3]. - After the lock-up period, shareholders are required to disclose control arrangements and can only sell up to 25% of their shares annually while adhering to specific pricing conditions [3][6]. Group 3: Compliance and Oversight - The company will ensure that shareholders comply with relevant regulations and commitments regarding share sales, including the "Interim Measures for the Management of Shareholder Share Reduction" [16]. - The company’s board will monitor compliance and report on shareholder adherence to commitments in regular disclosures [16]. Group 4: Changes in Share Capital Structure - As of the announcement date, the total share capital stands at 109,228,284 shares, with 39,600,000 shares still under lock-up [2][17]. - The lifting of the lock-up will not change the overall share capital structure, maintaining the total at 109,228,284 shares [17]. Group 5: Underwriting and Verification - The underwriting institution has verified that the application for lifting the lock-up aligns with regulatory requirements and that shareholders have adhered to their commitments made during the IPO [17][18].
百诚医药: 关于首次公开发行前已发行部分股份上市流通的提示性公告